Magnesium Bisglycinate
Last reviewed
Magnesium bisglycinate is magnesium chelated to two glycine molecules, the form with the best absorption and the cleanest gut profile for mast-cell-sensitive patients. It stabilizes mast cells by competing at calcium channels, supports HRV in POTS, and serves as a foundational electrolyte. ZebraThrive uses 300 mg elemental daily (from 2,400 mg bisglycinate) in the Daily Powder, split AM and PM.
At a Glance
Daily Dose
300 mg elemental magnesium daily from 2,400 mg magnesium bisglycinate, in the Daily Powder, split AM and PM scoops (per v7.8 RFQ)
Key Benefits
How It Works
Magnesium is involved in over 300 enzymatic reactions. In the triad, three functions matter most.
First, magnesium stabilizes mast cells by competing at calcium channels. Mast cell degranulation is triggered by calcium influx; adequate magnesium dampens that influx. A 2025 in vitro study showed magnesium reduces mast cell degranulation in a dose-dependent manner. Magnesium deficiency does the opposite: in animal data, deficient rats run 4-5 fold higher blood histamine within two weeks.
Second, magnesium modulates the autonomic nervous system. It supports parasympathetic ("rest and digest") tone and improves heart rate variability. For POTS specifically, this matters because autonomic instability is the core mechanism of the condition.
Third, the bisglycinate form delivers ~2g of glycine daily as a useful byproduct. Glycine supports sleep architecture and is a primary amino acid in collagen synthesis. DAO itself, the enzyme that degrades histamine in the gut, is copper-dependent rather than magnesium-dependent; magnesium's contribution to histamine handling is upstream, through the calcium-channel and deficiency-correction mechanisms above.
What the Research Shows
Recent research provides definitive evidence that magnesium stabilizes-not activates-mast cells.
In vitro study using rat peritoneal mast cells (2025)
Magnesium chloride reduced degranulating mast cells in a dose-dependent manner-first definitive in vitro evidence
In vivo rat model (2023)
Magnesium reduced mast cell degranulation by ~23% in acute phase and ~40% in second phase
Magnesium supplementation improves heart rate variability and autonomic balance.
Controlled trial, 32 heart failure patients, 300 mg/day
HRV correlation dimension significantly improved from 3.47 to 3.94 (p<0.001)
Magnesium deficiency triggers mast cell activation and is extremely common in this population.
Animal model of magnesium depletion
Magnesium-depleted rats showed 4-5 fold increased blood histamine by day 14 with massive degranulation
Addressing the Triad
Tailored benefits for complex conditions
Magnesium doesn't get enough credit for MCAS. Correcting low magnesium status removes a major upstream trigger for mast cell misbehavior, and the form choice matters: we use bisglycinate because it is free of the citric acid and sulfate excipients other magnesium forms often carry, both of which trigger flares in sensitive patients. Bisglycinate is also not fermentation-derived (unlike citrate), so no histamine or tyramine contamination risk.
For hEDS specifically, the most reliable benefits are practical: less muscle tension, fewer cramps, calmer sympathetic tone, better sleep. Animal and lab studies also show magnesium can inhibit MMPs (the enzymes that degrade collagen), adding an ECM-protective angle on top of the symptomatic relief. People with hEDS often describe magnesium as the supplement that makes everything else work better, the foundation that lets the rest of the protocol do its job.
Magnesium has some of the cleanest evidence of any supplement on this list for POTS-relevant outcomes. Multiple RCTs show improvements in heart rate variability - the autonomic stability marker that's directly impaired in POTS. A 2025 trial of 155 people on magnesium bisglycinate specifically showed better sleep quality and improved HRV readiness scores. The mechanism is layered: magnesium dampens sympathetic dominance, supports inhibitory neurotransmission through glycine, and helps your nervous system actually rest. We split the dose AM and PM to maintain steady levels instead of dumping it all at once.
Why We Chose This Form
We use magnesium bisglycinate - magnesium chelated to two glycine amino acids. The chelate gets absorbed through PepT1, the peptide transporter, instead of the routes that cause the laxative effect of citrate or oxide. Albion's TRAACS form is the preferred sourcing because the chelation is verified analytically - many cheaper 'bisglycinate' products are actually magnesium oxide buffered with glycine, not true chelate. We deliver 2,400 mg of the bisglycinate salt to give you 300 mg of elemental magnesium - the dose with actual HRV and sleep trial data in human studies.
Form Comparison
Magnesium oxide
Only 4-15% absorption; strong laxative effect
Magnesium citrate
~30% absorption; fermentation-derived = histamine risk
Magnesium glycinate
High absorption; minimal GI upset; glycine benefits
Magnesium L-threonate
Brain-penetrant alternative for cognitive symptoms; not what we ship
Safety & Interactions
Potential Side Effects
Magnesium glycinate is the best-tolerated form for GI-sensitive patients. Diarrhea can occur if dose is increased too rapidly. Theoretical concern of hypotension exists but is usually not significant in normotensive populations.
Drug Interactions
Antibiotics: Space by 2-6 hours. Bisphosphonates: Separate by 2+ hours. Thyroid medications: Space 2-4 hours. Fludrocortisone: Monitor electrolytes.
Excipients to Avoid
- Fermentation-derived citrate
- Magnesium stearate
- Artificial colors
Safe Excipients
- Magnesium glycinate from Albion chelate
- Powder form (eliminates fillers)
Monitor blood pressure when initiating. Kidney function should be normal. Paradoxical reactions occur in 25-30% of MCAS patients; try a different form if this happens.
How to Start
| Protocol Step | Suggested Dosage | Key Notes |
|---|---|---|
| Week 1 | 100 mg elemental | MCAS ultra-sensitive start |
| Week 2 | 125 mg twice daily | Standard start |
| Week 3 | 150 mg twice daily | Target maintenance |
| Week 4+ | 300 mg elemental daily | Full therapeutic dose, split AM/PM |
"RBC magnesium repletion requires 8-12 weeks. Don't expect immediate effects-repletion takes time. Sleep benefits may appear within 2-4 weeks."
State of the Evidence
No randomized controlled trials exist specifically testing magnesium glycinate in hEDS, POTS, or MCAS. One hEDS study found 59/94 patients had low RBC magnesium. Despite limited trials, 61-81% of hEDS patients report taking magnesium, reflecting widespread clinical use.
- [1]Magnesium and zinc stabilize mast cells in a dose-dependent mannerPMID: 40692390
Kazama I et al. (2025)
- [2]Magnesium reduces mast cell degranulation in orofacial pain modelPMID: 37047214
Srebro D et al. (2023)
- [3]Magnesium administration and heart rate variabilityPMID: 19201586
Almoznino-Sarafian D et al. (2009)
- [4]Bioavailability of magnesium diglycinate vs magnesium oxidePMID: 7815675
Schuette SA et al. (1994)
- [5]Kraeuter SL & Schwartz R, "Magnesium deficiency and histamine"PMID: 6445415
Common Questions
Written by Ken Chapman, Founder of ZebraThrive. Reviewed and last updated .